xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06003283</url>
    </required_header>
    <id_info>
      <org_study_id>S67309</org_study_id>
      <nct_id>NCT06003283</nct_id>
    </id_info>
    <brief_title>Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid Arthritis</brief_title>
    <acronym>RITUXERA</acronym>
    <official_title>Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid Arthritis: The RITUXERA Trial</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Universitaire Ziekenhuizen KU Leuven</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
      <collaborator>
        <agency>Fonds voor Wetenschappelijk Reumaonderzoek (FWRO)</agency>
        <agency_class>Other</agency_class>
      </collaborator>
    </sponsors>
    <source>Universitaire Ziekenhuizen KU Leuven</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
      <is_us_export>No</is_us_export>
    </oversight_info>
    <brief_summary>
      <textblock>
        The goal of this open label multicenter randomized controlled pragmatic superiority trial is&#xD;
        to investigate the optimal treatment/tapering strategy with rituximab for patients with&#xD;
        rheumatoid arthritis.&#xD;
  &#xD;
        The main questions it aims to answer are:&#xD;
  &#xD;
          -  What is the optimal treatment/tapering strategy for rituximab in patients with&#xD;
             rheumatoid arthritis in terms of reducing patient reported disease impact?&#xD;
  &#xD;
          -  What is the optimal treatment/tapering strategy for rituximab in patients with&#xD;
             rheumatoid arthritis in terms of therapeutic efficacy?&#xD;
  &#xD;
        Participants will be randomized to one of two study arms:&#xD;
  &#xD;
          -  Tapering based on disease-activity guided dose reduction (experimental arm)&#xD;
  &#xD;
          -  Tapering based on interval prolongation (active comparator arm)&#xD;
      </textblock>
    </brief_summary>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">November 1, 2023</start_date>
    <completion_date type="Anticipated">November 1, 2026</completion_date>
    <primary_completion_date type="Anticipated">November 1, 2026</primary_completion_date>
    <phase>Phase 4</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Parallel Assignment</intervention_model>
      <intervention_model_description>Open label multicenter pragmatic randomized controlled superiority trial. Patients will be 1:1 randomized to either the experimental arm or the active comparator arm.&#xD;
  Study visits are scheduled every 12 weeks (3 months). Recruitment period: 1 year. Trial duration: 2 years.</intervention_model_description>
      <primary_purpose>Treatment</primary_purpose>
      <masking>None (Open Label)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Comparison of disease impact in both study arms, measured using the Rheumatoid Arthritis Impact of Disease (RAID) questionnaire</measure>
      <time_frame>Over 2 years (104 weeks)</time_frame>
      <description>RAID questionnaire score range: 0 - 10, with higher scores indicating worse status.</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Comparison of disease activity in both study arms, measured using the Disease Activity Score in 28 joints - C-reactive protein (DAS28-CRP)</measure>
      <time_frame>Over 2 years (104 weeks)</time_frame>
      <description>Main secondary outcome. DAS28-CRP range: 0 - ..., with higher values indicating higher disease activity.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Comparison of disease activity in both study arms, measured using the Simplified Disease Activity Index (SDAI)</measure>
      <time_frame>Over 2 years (104 weeks)</time_frame>
      <description>SDAI range: 0 - ..., with higher values indicating higher disease activity.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Comparison of cumulative dose of rituximab in both study arms</measure>
      <time_frame>Over 2 years (104 weeks)</time_frame>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Comparison of cumulative dose of glucocorticoids in both study arms</measure>
      <time_frame>Over 2 years (104 weeks)</time_frame>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Proportion of patients in both study arms achieving a good or moderate European League Against Rheumatism (EULAR) treatment response after administration of rituximab, over a period of 2 years (104 weeks)</measure>
      <time_frame>Over 2 years (104 weeks)</time_frame>
      <description>A good EULAR response is defined as a decrease in Disease Activity Score in 28 joints - C-reactive protein (DAS28-CRP) &gt; 1.2 and a present DAS-CRP ≤ 3.2. A moderate EULAR response is defined as a decrease in DAS28-CRP &gt; 0.6 to ≤ 1.2 and a present DAS28-CRP ≤ 5.1, or a decrease in DAS28-CRP &gt; 1.2 and a present DAS28-CRP &gt; 3.2. Treatment responses will be evaluated 12 weeks after every administration of rituximab.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Comparison of loss of disease control in both study arms</measure>
      <time_frame>Over 2 years (104 weeks)</time_frame>
      <description>Loss of disease control is defined as achieving a Disease Activity Score in 28 joints - C-reactive protein (DAS28-CRP) &gt; 3.2 with previous DAS28-CRP ≤ 3.2.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Comparison of rituximab drug retention rate in both study arms</measure>
      <time_frame>Over 2 years (104 weeks)</time_frame>
      <description>Defined as the percentage of patients remaining on treatment with rituximab over time.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Proportion of patients tapering rituximab below 1000 mg in the experimental arm</measure>
      <time_frame>Over 2 years (104 weeks)</time_frame>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Mean/median interval between rituximab administrations in the active comparator group</measure>
      <time_frame>Over 2 years (104 weeks)</time_frame>
    </secondary_outcome>
    <other_outcome>
      <measure>Comparison of functional status in both study arms, measured using the Health Assessment Questionnaire - Disability Index (HAQ-DI)</measure>
      <time_frame>Over 2 years (104 weeks)</time_frame>
      <description>HAQ-DI score range: 0 - 3, with higher scores indicating worse functional status.</description>
    </other_outcome>
    <other_outcome>
      <measure>Self-efficacy in both study arms, measured using the Arthritis Self-Efficacy Scale (ASES)</measure>
      <time_frame>Over 2 years (104 weeks)</time_frame>
      <description>ASES score range: 11 - 110, with higher scores indicating higher perceived self-efficacy.</description>
    </other_outcome>
    <other_outcome>
      <measure>Pain in both study arms, measured using a Visual Analogue Scale (VAS) completed by the patient</measure>
      <time_frame>Over 2 years (104 weeks)</time_frame>
      <description>VAS pain range: 0 - 100, with higher values indicating higher pain</description>
    </other_outcome>
    <other_outcome>
      <measure>Fatigue in both study arms, measured using a Visual Analogue Scale (VAS) completed by the patient</measure>
      <time_frame>Over 2 years (104 weeks)</time_frame>
      <description>VAS fatigue range: 0 - 100, with higher values indicating more fatigue.</description>
    </other_outcome>
    <other_outcome>
      <measure>Patient global assessment (PGA) of disease in both study arms, measured using a Visual Analogue Scale (VAS) completed by the patient</measure>
      <time_frame>Over 2 years (104 weeks)</time_frame>
      <description>VAS PGA range: 0 - 100, with higher values indicating worse disease.</description>
    </other_outcome>
    <other_outcome>
      <measure>(Serious) infection rate in both study arms</measure>
      <time_frame>Over 2 years (104 weeks)</time_frame>
      <description>An infection is considered serious if it leads to inpatient hospitalization or prolongation of existing hospitalization, if it results in persistent or significant disability or incapacity, if it results in a life-threatening experience (meaning that the subject was at risk of death), or if it results in death.</description>
    </other_outcome>
    <other_outcome>
      <measure>Cluster of Differentiation (CD) 19+ and Memory B cell counts in both study arms</measure>
      <time_frame>Over 2 years (104 weeks)</time_frame>
      <description>Determined at baseline, before administration of rituximab and at year 2 (104 weeks) in both study arms.</description>
    </other_outcome>
    <other_outcome>
      <measure>Immunoglobulin (Ig) counts (IgG, IgA and IgM) in both study arms</measure>
      <time_frame>Over 2 years (104 weeks)</time_frame>
      <description>Determined at baseline, before administration of rituximab and at year 2 (104 weeks) in both study arms.</description>
    </other_outcome>
    <other_outcome>
      <measure>Professional and vocational participation in both study arms, calculated using the Work Productivity and Activity Impairment questionnaire: General Health (WPAI:GH)</measure>
      <time_frame>Over 2 years (104 weeks)</time_frame>
      <description>The WPAI:GH calculates the percent work time missed due to health, the percent impairment while working due to health, the percent overall work impairment due to health, and the percent activity impairment due to health.</description>
    </other_outcome>
    <other_outcome>
      <measure>Health utility index in both study arms, calculated using the summary index score of the EuroQol - 5 dimensions (EQ-5D) questionnaire</measure>
      <time_frame>Over 2 years (104 weeks)</time_frame>
      <description>Summary index score range: less than 0 (health state worse than dead, 0 being the value of a health state equivalent to death) to 1 (full health).</description>
    </other_outcome>
    <number_of_arms>2</number_of_arms>
    <enrollment type="Anticipated">134</enrollment>
    <condition>Rheumatoid Arthritis</condition>
    <arm_group>
      <arm_group_label>Tapering of rituximab based on disease activity guided dose reduction</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Treatment with rituximab every 6 months (24 weeks) with dosing based on disease activity, measured by the DAS28-CRP.&#xD;
  DAS28-CRP ≤ 3.2: dose reduction according to the following sequence: 1 x 1000 mg IV (maximum), 1 x 500 mg IV, 1 x 200 mg IV (minimum).&#xD;
  DAS28-CRP &gt; 3.2: administration of previously effective dose.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Tapering of rituximab based on interval prolongation</arm_group_label>
      <arm_group_type>Active Comparator</arm_group_type>
      <description>Treatment with fixed dose of rituximab (1 x 1000 mg IV) if DAS28-CRP ≥ 3.2 AND interval of at least 6 months (24 weeks) since previous administration of rituximab.</description>
    </arm_group>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Rituximab</intervention_name>
      <description>IV rituximab</description>
      <arm_group_label>Tapering of rituximab based on disease activity guided dose reduction</arm_group_label>
      <arm_group_label>Tapering of rituximab based on interval prolongation</arm_group_label>
      <other_name>MabThera</other_name>
      <other_name>Truxima</other_name>
      <other_name>Ruxience</other_name>
      <other_name>Rixathon</other_name>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Able and willing to give written informed consent and participate in the study before&#xD;
               any study procedure.&#xD;
  &#xD;
            -  Age ≥ 18 years.&#xD;
  &#xD;
            -  Understanding and able to write in Dutch or French.&#xD;
  &#xD;
            -  Diagnosis of rheumatoid arthritis according to the 2010 American College of&#xD;
               Rheumatology/European League Against Rheumatism (ACR/EULAR) Classification Criteria&#xD;
               for rheumatoid arthritis.&#xD;
  &#xD;
            -  Previous response to rituximab, defined as a minimum of one successful rituximab cycle&#xD;
               (= a moderate/good EULAR response 16 weeks after the first administration of&#xD;
               rituximab).&#xD;
  &#xD;
            -  Current treatment with rituximab.&#xD;
  &#xD;
            -  Need for a subsequent rituximab cycle according to the Belgian reimbursement criteria&#xD;
               for the use of rituximab in rheumatoid arthritis (DAS28 score ≥3.2).&#xD;
  &#xD;
            -  Stable dose of methotrexate or other conventional synthetic disease-modifying&#xD;
               antirheumatic drugs (DMARDs) 4 weeks prior to baseline.&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Current treatment with another biological DMARD than rituximab.&#xD;
  &#xD;
            -  Current treatment with a targeted synthetic DMARD.&#xD;
  &#xD;
            -  Pregnancy or pregnancy wish.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Patrick Verschueren, MD, PhD</last_name>
      <role>Principal Investigator</role>
      <affiliation>University Hospitals Leuven/KU Leuven</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Patrick Verschueren, MD, PhD</last_name>
      <phone>016342541</phone>
      <phone_ext>+32</phone_ext>
      <email>patrick.verschueren@uzleuven.be</email>
    </overall_contact>
    <overall_contact_backup>
      <last_name>Johan Joly, MSc</last_name>
      <phone>016340258</phone>
      <phone_ext>+32</phone_ext>
      <email>johan.joly@uzleuven.be</email>
    </overall_contact_backup>
    <location>
      <facility>
        <name>ZNA Jan Palfijn</name>
        <address>
          <city>Merksem</city>
          <state>Antwerpen</state>
          <zip>2170</zip>
          <country>Belgium</country>
        </address>
      </facility>
      <contact>
        <last_name>Alla Ishchenko, MD</last_name>
      </contact>
    </location>
    <location>
      <facility>
        <name>Reumacentrum Genk</name>
        <address>
          <city>Genk</city>
          <state>Limburg</state>
          <zip>3600</zip>
          <country>Belgium</country>
        </address>
      </facility>
      <contact>
        <last_name>Philip Remans, MD, PhD</last_name>
      </contact>
    </location>
    <location>
      <facility>
        <name>ReumaClinic Genk</name>
        <address>
          <city>Genk</city>
          <state>Limburg</state>
          <zip>3600</zip>
          <country>Belgium</country>
        </address>
      </facility>
      <contact>
        <last_name>Johan Vanhoof, MD</last_name>
      </contact>
    </location>
    <location>
      <facility>
        <name>OLV Aalst</name>
        <address>
          <city>Aalst</city>
          <state>Oost-Vlaanderen</state>
          <zip>9300</zip>
          <country>Belgium</country>
        </address>
      </facility>
      <contact>
        <last_name>Tom Zwaenepoel, MD</last_name>
      </contact>
    </location>
    <location>
      <facility>
        <name>RZ Heilig Hart</name>
        <address>
          <city>Leuven</city>
          <state>Vlaams-Brabant</state>
          <zip>3000</zip>
          <country>Belgium</country>
        </address>
      </facility>
      <contact>
        <last_name>Veerle Taelman, MD</last_name>
      </contact>
    </location>
    <location>
      <facility>
        <name>University Hospitals Leuven (UZ Leuven)</name>
        <address>
          <city>Leuven</city>
          <state>Vlaams-Brabant</state>
          <zip>3000</zip>
          <country>Belgium</country>
        </address>
      </facility>
      <contact>
        <last_name>Patrick Verschueren, MD, PhD</last_name>
      </contact>
      <contact_backup>
        <last_name>Johan Joly, MSc</last_name>
      </contact_backup>
      <investigator>
        <last_name>Elias De Meyst, MD</last_name>
        <role>Sub-Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Cliniques Universitaires Saint-Luc Bruxelles</name>
        <address>
          <city>Brussel</city>
          <zip>1000</zip>
          <country>Belgium</country>
        </address>
      </facility>
    </location>
    <location_countries>
      <country>Belgium</country>
    </location_countries>
    <verification_date>July 2023</verification_date>
    <study_first_submitted>July 19, 2023</study_first_submitted>
    <study_first_submitted_qc>August 17, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 21, 2023</study_first_posted>
    <last_update_submitted>August 17, 2023</last_update_submitted>
    <last_update_submitted_qc>August 17, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 21, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <keyword>Rheumatoid arthritis</keyword>
    <keyword>Rituximab</keyword>
    <keyword>Tapering</keyword>
    <keyword>Disease impact</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Arthritis</mesh_term>
      <mesh_term>Arthritis, Rheumatoid</mesh_term>
    </condition_browse>
    <intervention_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Rituximab</mesh_term>
    </intervention_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06003283
  org study id: S67309
  nct id: NCT06003283
  lead sponsor: 
  collaborator: 
  has dmc: No
  is fda regulated drug: No
  is fda regulated device: No
  is us export: No
  The goal of this open label multicenter randomized controlled pragmatic superiority trial is
        to investigate the optimal treatment/tapering strategy with rituximab for patients with
        rheumatoid arthritis.
  
        The main questions it aims to answer are:
  
          -  What is the optimal treatment/tapering strategy for rituximab in patients with
             rheumatoid arthritis in terms of reducing patient reported disease impact?
  
          -  What is the optimal treatment/tapering strategy for rituximab in patients with
             rheumatoid arthritis in terms of therapeutic efficacy?
  
        Participants will be randomized to one of two study arms:
  
          -  Tapering based on disease-activity guided dose reduction (experimental arm)
  
          -  Tapering based on interval prolongation (active comparator arm)
  allocation: Randomized
  intervention model: Parallel Assignment
  intervention model description: Open label multicenter pragmatic randomized controlled superiority trial. Patients will be 1:1 randomized to either the experimental arm or the active comparator arm.
  Study visits are scheduled every 12 weeks (3 months). Recruitment period: 1 year. Trial duration: 2 years.
  primary purpose: Treatment
  masking: None (Open Label)
  measure: Comparison of disease impact in both study arms, measured using the Rheumatoid Arthritis Impact of Disease (RAID) questionnaire
  time frame: Over 2 years (104 weeks)
  description: RAID questionnaire score range: 0 - 10, with higher scores indicating worse status.
  measure: Comparison of disease activity in both study arms, measured using the Disease Activity Score in 28 joints - C-reactive protein (DAS28-CRP)
  time frame: Over 2 years (104 weeks)
  description: Main secondary outcome. DAS28-CRP range: 0 - ..., with higher values indicating higher disease activity.
  measure: Comparison of disease activity in both study arms, measured using the Simplified Disease Activity Index (SDAI)
  time frame: Over 2 years (104 weeks)
  description: SDAI range: 0 - ..., with higher values indicating higher disease activity.
  measure: Comparison of cumulative dose of rituximab in both study arms
  time frame: Over 2 years (104 weeks)
  measure: Comparison of cumulative dose of glucocorticoids in both study arms
  time frame: Over 2 years (104 weeks)
  measure: Proportion of patients in both study arms achieving a good or moderate European League Against Rheumatism (EULAR) treatment response after administration of rituximab, over a period of 2 years (104 weeks)
  time frame: Over 2 years (104 weeks)
  description: A good EULAR response is defined as a decrease in Disease Activity Score in 28 joints - C-reactive protein (DAS28-CRP) > 1.2 and a present DAS-CRP ≤ 3.2. A moderate EULAR response is defined as a decrease in DAS28-CRP > 0.6 to ≤ 1.2 and a present DAS28-CRP ≤ 5.1, or a decrease in DAS28-CRP > 1.2 and a present DAS28-CRP > 3.2. Treatment responses will be evaluated 12 weeks after every administration of rituximab.
  measure: Comparison of loss of disease control in both study arms
  time frame: Over 2 years (104 weeks)
  description: Loss of disease control is defined as achieving a Disease Activity Score in 28 joints - C-reactive protein (DAS28-CRP) > 3.2 with previous DAS28-CRP ≤ 3.2.
  measure: Comparison of rituximab drug retention rate in both study arms
  time frame: Over 2 years (104 weeks)
  description: Defined as the percentage of patients remaining on treatment with rituximab over time.
  measure: Proportion of patients tapering rituximab below 1000 mg in the experimental arm
  time frame: Over 2 years (104 weeks)
  measure: Mean/median interval between rituximab administrations in the active comparator group
  time frame: Over 2 years (104 weeks)
  measure: Comparison of functional status in both study arms, measured using the Health Assessment Questionnaire - Disability Index (HAQ-DI)
  time frame: Over 2 years (104 weeks)
  description: HAQ-DI score range: 0 - 3, with higher scores indicating worse functional status.
  measure: Self-efficacy in both study arms, measured using the Arthritis Self-Efficacy Scale (ASES)
  time frame: Over 2 years (104 weeks)
  description: ASES score range: 11 - 110, with higher scores indicating higher perceived self-efficacy.
  measure: Pain in both study arms, measured using a Visual Analogue Scale (VAS) completed by the patient
  time frame: Over 2 years (104 weeks)
  description: VAS pain range: 0 - 100, with higher values indicating higher pain
  measure: Fatigue in both study arms, measured using a Visual Analogue Scale (VAS) completed by the patient
  time frame: Over 2 years (104 weeks)
  description: VAS fatigue range: 0 - 100, with higher values indicating more fatigue.
  measure: Patient global assessment (PGA) of disease in both study arms, measured using a Visual Analogue Scale (VAS) completed by the patient
  time frame: Over 2 years (104 weeks)
  description: VAS PGA range: 0 - 100, with higher values indicating worse disease.
  measure: (Serious) infection rate in both study arms
  time frame: Over 2 years (104 weeks)
  description: An infection is considered serious if it leads to inpatient hospitalization or prolongation of existing hospitalization, if it results in persistent or significant disability or incapacity, if it results in a life-threatening experience (meaning that the subject was at risk of death), or if it results in death.
  measure: Cluster of Differentiation (CD) 19+ and Memory B cell counts in both study arms
  time frame: Over 2 years (104 weeks)
  description: Determined at baseline, before administration of rituximab and at year 2 (104 weeks) in both study arms.
  measure: Immunoglobulin (Ig) counts (IgG, IgA and IgM) in both study arms
  time frame: Over 2 years (104 weeks)
  description: Determined at baseline, before administration of rituximab and at year 2 (104 weeks) in both study arms.
  measure: Professional and vocational participation in both study arms, calculated using the Work Productivity and Activity Impairment questionnaire: General Health (WPAI:GH)
  time frame: Over 2 years (104 weeks)
  description: The WPAI:GH calculates the percent work time missed due to health, the percent impairment while working due to health, the percent overall work impairment due to health, and the percent activity impairment due to health.
  measure: Health utility index in both study arms, calculated using the summary index score of the EuroQol - 5 dimensions (EQ-5D) questionnaire
  time frame: Over 2 years (104 weeks)
  description: Summary index score range: less than 0 (health state worse than dead, 0 being the value of a health state equivalent to death) to 1 (full health).
  arm group label: Tapering of rituximab based on disease activity guided dose reduction
  arm group type: Experimental
  description: Treatment with rituximab every 6 months (24 weeks) with dosing based on disease activity, measured by the DAS28-CRP.
  DAS28-CRP ≤ 3.2: dose reduction according to the following sequence: 1 x 1000 mg IV (maximum), 1 x 500 mg IV, 1 x 200 mg IV (minimum).
  DAS28-CRP > 3.2: administration of previously effective dose.
  arm group label: Tapering of rituximab based on interval prolongation
  arm group type: Active Comparator
  description: Treatment with fixed dose of rituximab (1 x 1000 mg IV) if DAS28-CRP ≥ 3.2 AND interval of at least 6 months (24 weeks) since previous administration of rituximab.
  intervention type: Drug
  intervention name: Rituximab
  description: IV rituximab
  arm group label: Tapering of rituximab based on disease activity guided dose reduction
  arm group label: Tapering of rituximab based on interval prolongation
  other name: MabThera
  other name: Truxima
  other name: Ruxience
  other name: Rixathon
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: N/A
  healthy volunteers: No
  last name: Patrick Verschueren, MD, PhD
  role: Principal Investigator
  affiliation: University Hospitals Leuven/KU Leuven
  last name: Patrick Verschueren, MD, PhD
  phone: 016342541
  phone ext: +32
  email: patrick.verschueren@uzleuven.be
  last name: Johan Joly, MSc
  phone: 016340258
  phone ext: +32
  email: johan.joly@uzleuven.be
  facility: 
  contact: 
  facility: 
  contact: 
  facility: 
  contact: 
  facility: 
  contact: 
  facility: 
  contact: 
  facility: 
  contact: 
  contact backup: 
  investigator: 
  facility: 
  country: Belgium
  responsible party type: Sponsor
  mesh term: Arthritis
  mesh term: Arthritis, Rheumatoid
  mesh term: Rituximab
  sharing ipd: No